TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02426632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.
Study: NCT00591526

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Arac
Description: Ommit ARAC in the chemotherapy
Study: NCT02426632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C
Description: 10 mg/mL oral solution containing 10 mg/mL sucralose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C
Description: 10 mg/mL oral solution containing 10 mg/mL sucralose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C
Description: 10 mg/mL oral solution containing 10 mg/mL sucralose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C
Description: 10 mg/mL oral solution containing 10 mg/mL sucralose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C
Description: 10 mg/mL oral solution containing 10 mg/mL sucralose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation C
Description: 10 mg/mL oral solution containing 10 mg/mL sucralose.
Study: NCT03534687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: 12-week supervised aerobic exercise
Study: NCT01199939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine
Description: 400mg once daily orally for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100mg once daily orally for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 800mg once daily orally for 48 weeks
Study: NCT02896634

Intervention type: BIOLOGICAL
Intervention: clinical biology analyzes spectrometry mass
Description: clinical biology analyzes spectrometry mass

Intervention type: BIOLOGICAL
Intervention: clinical biology analyzes spectrometry mass
Description: clinical biology analyzes spectrometry mass

Intervention type: BIOLOGICAL
Intervention: clinical biology analyzes spectrometry mass
Description: clinical biology analyzes spectrometry mass
Study: NCT02426632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose and raspberry flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose and raspberry flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation D
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose and raspberry flavor.
Study: NCT01973270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuroadaptive cognitive training
Description: TCT exercises consist of three modules: an Auditory Processing Module (40-50 hours of training); a Visual Processing Module (30 hours); a Cognitive Control Module prototype (20 hours). \[Based on the results of our current RCT, Posit Science has revised aspects of the training modules in order to further optimize its effectiveness for treatment of schizophrenia. In this study, we will use updated versions of the training software: an Auditory Module (20 hours), and a Social Module (10 hours). Features from the Cognitive Control module prototype have been expanded and incorporated into these new modules.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuroadaptive cognitive training
Description: TCT exercises consist of three modules: an Auditory Processing Module (40-50 hours of training); a Visual Processing Module (30 hours); a Cognitive Control Module prototype (20 hours). \[Based on the results of our current RCT, Posit Science has revised aspects of the training modules in order to further optimize its effectiveness for treatment of schizophrenia. In this study, we will use updated versions of the training software: an Auditory Module (20 hours), and a Social Module (10 hours). Features from the Cognitive Control module prototype have been expanded and incorporated into these new modules.
Study: NCT02146235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-Music Therapy
Study: NCT02517099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclometasone
Description: Beclometasone dipropionate 200mcg bd for 4 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclometasone
Description: Beclometasone dipropionate 200mcg bd for 4 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-amoxiclav
Description: Co-amoxiclav 0.3ml/kg bd for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-amoxiclav
Description: Co-amoxiclav 0.3ml/kg bd for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin 10mg/kg od for 4 weeks
Study: NCT02426632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.
Study: NCT02517099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin 10mg/kg od for 4 weeks
Study: NCT02426632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.
Study: NCT02538055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living Healthy
Description: This intervention tested the effects of a community health worker delivered lifestyle modification program based on cognitive behavioral therapy on diabetes and pain outcomes in individuals with diabetes and chronic pain.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Health Program
Description: Participants in this arm worked with a Community Health Worker (CHW) who provided a general health program that consisted of didactic information of unrelated general health information. Participants received the same number of contacts with their CHW as the intervention arm. Participants and CHW interacted by telephone 8 times over 3 months.
Study: NCT01717755

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment
Description: IA therapy has to be initiated within 6 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of IA strategy wil be made by the treating neurointerventionalist. Choice of therapy depends on local approval and experience. If IA thrombolysis is the chosen strategy, a maximum of 22 mg of IA rt-PA or 1.500.000 Units of Urokinase may be given. Stenting is allowed in the presence of a high-grade vertebral artery stenosis or occlusion hampering adequate endovascular access to the basilar artery and in case of a residual high-grade basilar artery stenosis. The use of any other treatment strategy depends on local approval and experience, and is only allowed after prior approval of the steering committee.
Study: NCT02426632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation E
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation F
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation F
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation F
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation F
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation F
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation F
Description: 10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation M1
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
Study: NCT00006747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transplant
Study: NCT03959579

Intervention type: DIAGNOSTIC_TEST
Intervention: systematic endomyocardial biopsy.
Description: We sought to compare the long term survival of HTx recipients followed with or without systematic endomyocardial biopsy. Second, the sensibility and specificity of cardiac echo to diagnose acute allograft rejection will be analyzed.~To show the safety of non-invasively monitoring HTx recipients without systematic endomyocardial biopsy
Study: NCT02260583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal CO2 device
Description: An ECCO2R device based on a modified continuous venovenous hemofiltration system will be used
Study: NCT00570804

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone Counseling
Description: 7 counseling calls where quit date set on first counseling call; then counseling calls on quit date, 3-5 days after quit date, 7-10 days after quit date, 15-30 days after quit date, 45-60 days after quit date, and 90 days after quit date, each taking about 15 to 30 minutes to complete.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone Counseling
Description: 7 counseling calls where quit date set on first counseling call; then counseling calls on quit date, 3-5 days after quit date, 7-10 days after quit date, 15-30 days after quit date, 45-60 days after quit date, and 90 days after quit date, each taking about 15 to 30 minutes to complete.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone Assessments
Description: 4 assessment telephone calls at Weeks 12, 26 and 52 (interview by a research staff member), taking about 30 minutes each to complete.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone Assessments
Description: 4 assessment telephone calls at Weeks 12, 26 and 52 (interview by a research staff member), taking about 30 minutes each to complete.
Study: NCT02633345

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic tablets
Description: Tablets with both Lactobacillus rhamnosus PB01 and Lactobacillus curvatus P2-2. Two tablets a day for four weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT02426632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation M1
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation M1
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation M1
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation M1
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation M1
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation M2
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation M2
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
Study: NCT02995265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton Program
Description: Subjects will wear the exoskeleton device at each physiotherapy session to work on improving mobility and walking ability.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Program
Description: Subjects will receive hands-on physiotherapy to improve their mobility and walking ability. Physiotherapy session will be tailored to subject individually by their therapist.
Study: NCT00951899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam
Description: Colesevelam hydrochloride; three 625mg tablets taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three placebo tablets matching the active drug colesevelam in appearance, taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Subjects were instructed to follow a weight maintenance diet (\~55% carbohydrate, 30% fat and 15% protein) for the 12 week study period.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diet
Description: Subjects were instructed to follow a weight maintenance diet (\~55% carbohydrate, 30% fat and 15% protein) for the 12 week study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Subjects continued to take their pre-study therapeutic doses of metformin (Metformin 500mg tablets taken by mouth twice daily for a total daily dose of 1000 to 2000 mg) through the 12 week study period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Subjects continued to take their pre-study therapeutic doses of metformin (Metformin 500mg tablets taken by mouth twice daily for a total daily dose of 1000 to 2000 mg) through the 12 week study period.
Study: NCT02426632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation M2
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation M2
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation M2
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation M2
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation M3
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation M3
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation M3
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation M3
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation M3
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation M3
Description: Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation N1
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation N1
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation N1
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation N1
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation N1
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
Study: NCT02151162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress management program
Description: Mindfulness-based stress management program will be conducted by senior nurses in four individual sessions within these three months. Senior nurses have taken a 7-hour workshop including lectures and role-playing sessions. The detailed manual and videos including lectures will be provided to the senior nurses.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based stress management program
Description: Mindfulness-based stress management program will be conducted by senior nurses in four individual sessions within these three months. Senior nurses have taken a 7-hour workshop including lectures and role-playing sessions. The detailed manual and videos including lectures will be provided to the senior nurses.
Study: NCT02426632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation N1
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation N2
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation N2
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation N2
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation N2
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation N2
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation N2
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation N3
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation N3
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation N3
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation N3
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation N3
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation N3
Description: Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).